Please wait while the formulary information is being retrieved.
ATROPINE SULFATE (ATROPINE SULFATE)
- Reversal of neuromuscular blockade
- Sialorrhea
- Sinus bradycardia
- Cholinesterase inhibitors toxicity
- Muscarine toxicity
- Organophosphorous overdose
0.05 mg/mL injection syringe
- Dosage information is not available
0.1 mg/mL injection syringe
- Dosage information is not available
atropine 0.05 mg/mL injection syringe
- Dosage information is not available
atropine 0.1 mg/mL injection syringe
- Dosage information is not available
- None
Contraindicated
- None
Severe
Moderate
- Adasuve
- chlorpromazine
- Compazine
- Compro
- fluphenazine decanoate
- fluphenazine HCl
- Haldol
- Haldol Decanoate
- haloperidol
- haloperidol decanoate
- haloperidol lactate
- loxapine
- loxapine succinate
- Loxitane
- perphenazine
- perphenazine-amitriptyline
- Phenadoz
- Phenergan
- prochlorperazine
- prochlorperazine Edisylate
- prochlorperazine maleate
- promethazine
- Promethazine Vc
- Promethazine Vc-codeine
- promethazine-codeine
- promethazine-DM
- promethazine-phenyleph-codeine
- promethazine-phenylephrine
- Promethegan
- thioridazine
- trifluoperazine
- Achalasia of esophagus
- Angle-closure glaucoma
- Atony of colon
- Bladder outflow obstruction
- Hemorrhagic shock
- Myasthenia gravis
- Paralytic ileus
- Pyloroduodenal obstruction
- Toxic megacolon
- Urinary tract obstructive uropathy
Contraindicated
- Autonomic dysreflexia
- Benign prostatic hyperplasia
- Gastric ulcer
- Gastrointestinal obstruction
- Hiatal hernia
- Reflux esophagitis
- Severe ulcerative colitis
- Tachyarrhythmia
- Toxin-mediated diarrhea
- Ulcerative colitis
- Urinary retention
Severe
Moderate
- Chronic heart failure
- Chronic pulmonary disease
- Coronary artery disease
- Disease of liver
- Down's syndrome
- Drowsy
- Hypertension
- Hyperthyroidism
- Kidney disease with reduction in GFR
- Salivary secretion disorder
ATROPINE SULFATE (ATROPINE SULFATE)
- Reversal of neuromuscular blockade
- Sialorrhea
- Sinus bradycardia
- Cholinesterase inhibitors toxicity
- Muscarine toxicity
- Organophosphorous overdose
- Palpitations
- Tachycardia
- Urinary retention
- Blurred vision
- Constipation
- Decreased sweating
- Dry eye
- Injection site sequelae
- Photophobia
- Urinary hesitancy
- Xerostomia
More Frequent
Severe
Less Severe
- None
- Abdominal distension
- Dizziness
- Drowsy
- Dry skin
- Mydriasis
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute confusion
- Acute myocardial infarction
- Anaphylaxis
- Atrial fibrillation
- Atrial flutter
- Dehydration
- Fever
- Hallucinations
- Hypersensitivity drug reaction
- Laryngismus
- Manic disorder
- Ocular hypertension
- Orthostatic hypotension
- Paralytic ileus
- Pyloroduodenal obstruction
- Respiration changes
- Secondary angle-closure glaucoma
- Seizure disorder
- Skin rash
- Urticaria
- Ventricular arrhythmias
- Ventricular fibrillation
- Ventricular premature beats
Less Severe
- Agitation
- Ataxia
- Concentration difficulty
- Dysphagia
- Dysuria
- Feeling of alcohol intoxication
- Flushing
- General weakness
- Headache disorder
- Hypertonia
- Insomnia
- Loss of taste
- Memory impairment
- Nausea
- Nervousness
- Petechiae
- Symptoms of anxiety
- Syncope
- Vertigo
- Vomiting
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Atropine
Infants and children are more sensitive to anticholinergic and adverse effects. Adverse CNS effects onset may be sooner and with lower dose.
- 1 Day – 13 Years
- Infants and children are more sensitive to anticholinergic and adverse effects. Adverse CNS effects onset may be sooner and with lower dose.
Atropine Sulfate (systemic)
- Severity Level:
2
- Additional Notes: Iv use may produce tachycardia in fetus
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Atropine
None
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Atropine
Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Cardiovascular-May cause orthostatic hypotension at higher doses. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | Y | N | N |
BEERS: Y HEDIS: Y STOPP: Y
No Known Risk
None
- None
| Cholinesterase inhibitors toxicity | |
| T44.0x1A | Poisoning by anticholinesterase agents, accidental (unintentional), initial encounter |
| T44.0x2A | Poisoning by anticholinesterase agents, intentional self-harm, initial encounter |
| T44.0x3A | Poisoning by anticholinesterase agents, assault, initial encounter |
| T44.0x4A | Poisoning by anticholinesterase agents, undetermined, initial encounter |
| Muscarine toxicity | |
| T44.1x1A | Poisoning by other parasympathomimetics [cholinergics], accidental (unintentional), initial encounter |
| T44.1x2A | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, initial encounter |
| T44.1x3A | Poisoning by other parasympathomimetics [cholinergics], assault, initial encounter |
| T44.1x4A | Poisoning by other parasympathomimetics [cholinergics], undetermined, initial encounter |
| Organophosphorous overdose | |
| T44.0x1A | Poisoning by anticholinesterase agents, accidental (unintentional), initial encounter |
| T44.0x2A | Poisoning by anticholinesterase agents, intentional self-harm, initial encounter |
| T44.0x3A | Poisoning by anticholinesterase agents, assault, initial encounter |
| T44.0x4A | Poisoning by anticholinesterase agents, undetermined, initial encounter |
| Reversal of neuromuscular blockade | |
| T48.1x1A | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], accidental (unintentional), initial encounter |
| T48.1x2A | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, initial encounter |
| T48.1x3A | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], assault, initial encounter |
| T48.1x4A | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], undetermined, initial encounter |
| T48.1x5A | Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter |
| Sialorrhea | |
| K11.7 | Disturbances of salivary secretion |
| Sinus bradycardia | |
| P29.12 | Neonatal bradycardia |
| R00.1 | Bradycardia, unspecified |
| 0-9 | A-Z |
|---|---|
| K11.7 | Disturbances of salivary secretion |
| P29.12 | Neonatal bradycardia |
| R00.1 | Bradycardia, unspecified |
| T44.0x1A | Poisoning by anticholinesterase agents, accidental (unintentional), initial encounter |
| T44.0x1A | Poisoning by anticholinesterase agents, accidental (unintentional), initial encounter |
| T44.0x2A | Poisoning by anticholinesterase agents, intentional self-harm, initial encounter |
| T44.0x2A | Poisoning by anticholinesterase agents, intentional self-harm, initial encounter |
| T44.0x3A | Poisoning by anticholinesterase agents, assault, initial encounter |
| T44.0x3A | Poisoning by anticholinesterase agents, assault, initial encounter |
| T44.0x4A | Poisoning by anticholinesterase agents, undetermined, initial encounter |
| T44.0x4A | Poisoning by anticholinesterase agents, undetermined, initial encounter |
| T44.1x1A | Poisoning by other parasympathomimetics [cholinergics], accidental (unintentional), initial encounter |
| T44.1x2A | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, initial encounter |
| T44.1x3A | Poisoning by other parasympathomimetics [cholinergics], assault, initial encounter |
| T44.1x4A | Poisoning by other parasympathomimetics [cholinergics], undetermined, initial encounter |
| T48.1x1A | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], accidental (unintentional), initial encounter |
| T48.1x2A | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, initial encounter |
| T48.1x3A | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], assault, initial encounter |
| T48.1x4A | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], undetermined, initial encounter |
| T48.1x5A | Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter |
Formulary Reference Tool